Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Emerging Strategies in Breast Cancer: Targeting Tomorrow's Therapies Today
Hyatt Regency Cambridge
Cambridge, MA
September 13, 2008
Saturday, Sep 13, 2008
| 7:30 am | Continental Breakfast |
| 7:50 am | Welcome, Introduction and Presession Survey |
| Genetics and Breast Cancer | |
| 8:00 am | Update on Breast Cancer Genetics Judy Garber |
| 8:20 am | Question-and-Answer Session |
| Advances in Chemotherapy for Early-Stage Breast Cancer | |
| 8:25 am | Advances in Chemotherapeutic Strategies for Early-Stage Breast Cancer Harold Burstein |
| 8:45 am | Question-and-Answer Session |
| 8:50 am | Molecular Assays for Adjuvant Therapy Selection G. Thomas Budd |
| 9:10 am | Question-and-Answer Session |
| Advances in Endocrine Therapy | |
| 9:15 am | Emerging Concepts in Endocrine Therapy Eric P. Winer |
| 9:35 am | Question-and-Answer Session |
| 9:40 am | New Agents Targeting Bone Julie R. Gralow |
| 10:00 am | Question-and-Answer Session |
| 10:05 am | Panel Discussion: Controversies in Chemotherapy and Endocrine Therapy |
| 10:25 am | Break |
| Advances in HER2-Targeted Therapy | |
| 10:40 am | Update on Adjuvant Therapy for HER2-Positive Breast Cancer Edward Romond |
| 11:00 am | Question-and-Answer Session |
| 11:05 am | Controversies in HER2 Testing William F. Symmans |
| 11:25 am | Question-and-Answer Session |
| 11:30 | Novel HER2-Targeted Agents Ian Krop |
| 11:50 am | Question-and-Answer Session |
| 11:55 am | New Approaches to Central Nervous System Metastases Nancy Uan-Tsin Lin |
| 12:15 pm | Question-and-Answer Session |
| 12:20 pm | Break |
| 12:35 pm | Working Lunch: ìAsk the Expertsî Roundtable and Panel Discussions Challenging patient cases emphasizing questions and controversial issues surrounding the integration of new therapeutic agents into the treatment of breast cancer and other approaches to breast cancer management |
| Novel Agents for Breast Cancer | |
| 1:30 pm | Novel Cytotoxic Agents for Metastatic Disease Beth Overmoyer |
| 1:50 pm | Question-and-Answer Session |
| 1:55 pm | Incorporating Angiogenesis Inhibition Into Breast Cancer Treatment Erica Mayer |
| 2:15 pm | Question-and-Answer Session |
| 2:20 pm | Targeting New Pathways: IGFR Inhibition Paula D. Ryan |
| 2:40 pm | Question-and-Answer Session |
| 2:45 pm | Understanding Triple-Negative Disease Eric P. Winer |
| 3:05 pm | Question-and-Answer Session |
| 3:10 pm | Break |
| Individualizing Therapy and Patient Management | |
| 3:25 pm | Germline Pharmacogenomics in the Use of Tamoxifen and Aromatase Inhibitors David Flockhart |
| 3:45 pm | Question-and-Answer Session |
| 3:50 pm | Measuring Compliance to Therapy Ann Partridge |
| 4:10 pm | Panel Discussion |
| 4:30 pm | Postsession Survey |
| 4:40 pm | Closing Comments Harold Burstein, Eric P. Winer |
| 5:00 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology
- Bristol-Myers Squibb
- GlaxoSmithKline
- Pfizer Oncology
- sanofi-aventis U.S.